Bases bactériologiques du traitement de la tuberculose.

Translated title of the contribution: Bacteriologic basis for the treatment of tuberculosis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


To be fully effective, short-course chemotherapy for tuberculosis should take into account the slow growth rate, high oxygen requirement and high drug-resistant mutant emergence rate of Mycobacterium tuberculosis, as well as the type of the lesions observed and the specific activity of each antituberculous drug. Due to their unique sterilizing activities against bacilli that are not actively metabolizing, rifampicin and pyrazinamide are the key drugs for short-course chemotherapy. To prevent the selection of drug-resistant mutants and the occurrence of therapeutic failures, a combination of isoniazid, rifampicin, pyrazinamide and ethambutol should be given during the first two months of treatment. To kill persisting M. tuberculosis, and thus avoid posttreatment relapses, the isoniazid-rifampicin combination should be prescribed for à further four months.

Translated title of the contributionBacteriologic basis for the treatment of tuberculosis
Original languageFrench
Pages (from-to)715-718
Number of pages4
JournalRevue du Praticien
Issue number8
StatePublished - Mar 11 1990
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Bacteriologic basis for the treatment of tuberculosis'. Together they form a unique fingerprint.

Cite this